ArticleJournal of current ophthalmology
Antivascular Endothelial Growth Factors for the Management of Choroidal Neovascularization Associated with Choroidal Osteoma: A Case Study-Based Review.
Article in Journal of current ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Use of Aflibercept to Treat Choroidal Neovascularization Secondary to Choroidal Osteoma in a 7-Year-Old Child: A Multimodal Imaging Case Report.Case reports in ophthalmological medicine · 2026Article
- Case Report: Faricimab in the treatment of subretinal fluid secondary to choroidal osteoma without definite evidence of CNV.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To present a 13-year-old patient with choroidal osteoma complicated by choroidal neovascularization (CNV) treated with antivascular endothelial growth factor (anti-VEGF) agents and to review the efficacy of these agents based on relevant literature. Methods: Case report. Results: A 13-year-old girl presented with sudden visual loss in her right eye. Ophthalmic examination revealed a large choroidal osteoma complicated by subretinal and subretinal pigment epithelium (sub-RPE) hemorrhage, suggestive of CNV. Intravitreal bevacizumab injections were administered, leading to substantial improvement in vision and resolution of subretinal and sub-RPE hemorrhage. Follow-up showed that further injections were unnecessary as the CNV regressed. Literature review identified 25 cases of CNV associated with choroidal osteoma, with bevacizumab being the most frequently used anti-VEGF agent. Multiple injections were often required, though single-dose injections also proved effective in some cases. The majority of patients experienced visual improvement following treatment. Conclusion: Anti-VEGF agents, like bevacizumab, appear to be a promising treatment option for CNV secondary to choroidal osteoma, potentially preserving and improving vision with limited injections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.